- Home
- MRM vs VINC Comparison
MRM vs VINC Comparison
Compare MRM & VINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- VINC
- Stock Information
- Founded
- MRM 2000
- VINC 2019
- Country
- MRM Japan
- VINC United States
- Employees
- MRM N/A
- VINC N/A
- Industry
- MRM Other Consumer Services
- VINC Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- VINC Health Care
- Exchange
- MRM Nasdaq
- VINC Nasdaq
- Market Cap
- MRM 12.2M
- VINC 10.7M
- IPO Year
- MRM 2020
- VINC N/A
- Fundamental
- Price
- MRM $2.51
- VINC $0.32
- Analyst Decision
- MRM
- VINC Buy
- Analyst Count
- MRM 0
- VINC 2
- Target Price
- MRM N/A
- VINC $2.00
- AVG Volume (30 Days)
- MRM 11.0K
- VINC 354.0K
- Earning Date
- MRM 12-30-2022
- VINC 11-12-2024
- Dividend Yield
- MRM N/A
- VINC N/A
- EPS Growth
- MRM N/A
- VINC N/A
- EPS
- MRM 0.16
- VINC N/A
- Revenue
- MRM $48,438,179.00
- VINC N/A
- Revenue This Year
- MRM N/A
- VINC N/A
- Revenue Next Year
- MRM N/A
- VINC N/A
- P/E Ratio
- MRM $16.64
- VINC N/A
- Revenue Growth
- MRM N/A
- VINC N/A
- 52 Week Low
- MRM $2.27
- VINC $0.29
- 52 Week High
- MRM $8.39
- VINC $9.37
- Technical
- Relative Strength Index (RSI)
- MRM 42.33
- VINC 31.82
- Support Level
- MRM $2.42
- VINC $0.31
- Resistance Level
- MRM $3.07
- VINC $0.38
- Average True Range (ATR)
- MRM 0.27
- VINC 0.03
- MACD
- MRM 0.00
- VINC 0.01
- Stochastic Oscillator
- MRM 31.00
- VINC 15.26
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.